Warfarin and Enoxaparin Dosing for Anticoagulation
Start warfarin at 5 mg daily (or 2-5 mg in elderly/debilitated patients), and bridge with enoxaparin 1 mg/kg subcutaneously every 12 hours until the INR is therapeutic (2.0-3.0) for at least 24 hours, typically requiring 4-5 days of overlap. 1
Warfarin Initiation
The FDA-approved warfarin label and current guidelines recommend starting with 5 mg daily for most patients 1. This approach balances efficacy with safety:
Avoid loading doses of 10 mg: While 10 mg may achieve therapeutic INR faster in some patients, the evidence is highly inconsistent and heterogeneous, with one study showing benefit, another showing harm, and a third showing no difference 2. Loading doses increase bleeding risk without providing better protection against thrombosis 1, 3.
Lower initial doses (2-5 mg) for specific populations 1:
- Elderly patients (≥60 years) - they exhibit greater INR response to warfarin
- Debilitated patients
- Patients with poor nutritional status
- Those with hepatic dysfunction
- Asian patients (may require mean doses as low as 3.3 mg daily)
- Patients with certain CYP2C9 or VKORC1 genetic variants
Common pitfall: Do not use 10 mg loading doses routinely. The evidence shows substantial heterogeneity (I² = 90%) with conflicting results across studies 2. The 5 mg starting dose is safer and FDA-recommended.
Enoxaparin Bridging Dose
Use enoxaparin 1 mg/kg subcutaneously every 12 hours for therapeutic anticoagulation while awaiting therapeutic INR 4, 5, 6, 5. This is the standard FDA-approved dose for VTE treatment.
Alternative dosing:
- 1.5 mg/kg once daily is also acceptable and widely used in clinical practice, though the 2014 AT9 guidelines recommend the full 2 mg/kg once daily dose for once-daily regimens 5
- For patients ≥75 years with fibrinolytic therapy: 0.75 mg/kg every 12 hours without IV bolus 7
- Renal impairment (CrCl <30 mL/min): Reduce to 1 mg/kg once daily 4, 5
Overlap Duration and Monitoring
Critical timing:
- Start warfarin on day 1 or 2 of enoxaparin therapy 8
- Continue enoxaparin for minimum 4-5 days AND until INR is ≥2.0 for at least 24 hours (preferably 2 consecutive days) 5, 6, 5, 8
- Check INR daily initially until stable in therapeutic range (2.0-3.0) 1
Do not stop enoxaparin prematurely: The anticoagulant effect of warfarin is delayed due to the time required to deplete existing clotting factors. Even if INR rises quickly, continue overlap for the full 4-5 days to ensure adequate anticoagulation 5, 8.
Key Safety Considerations
- Never switch between enoxaparin and UFH during treatment - this increases bleeding risk 7
- Target INR 2.0-3.0 for most indications (VTE, atrial fibrillation) 5, 1
- INR >4.0 provides no additional benefit and significantly increases bleeding risk 1
- Monitor for heparin-induced thrombocytopenia (HIT) if using UFH, though risk is much lower with enoxaparin 5
Cost and Practical Considerations
Starting with 5 mg warfarin (versus lower doses like 3 mg) actually reduces overall costs by achieving therapeutic INR faster, thereby shortening the duration of expensive enoxaparin bridging 9. The 5 mg dose achieved target INR in 5.3 days versus 6.6 days with 3 mg, with comparable bleeding rates.